EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 3.0

Thiazole–driven heterocyclic hybrids as EGFR inhibitors: progress in synthesis and anticancer applications

Ancilla Dsouza, V M Subrahmanyam, Nitinkumar S Shetty iD

RSC Advances · 2026 · 16 (1) · 510-567

DOI: 10.1039/d5ra04838a ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift RSC Advances, 2026. Verfasst von Ancilla Dsouza und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Manipal Institute of Technology, Manipal Academy of Higher Education Manipal Karnataka 576104 India nitin.shetty@manipal.edu. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An overview of the role and current landscape of EGFR inhibitors in cancer treatment, with a particular emphasis on recent progress in the design, synthesis, and development of novel thiazole hybrid compounds as promising selective EGFR TKIs.

Autor:innen und Institutionen

  • Department of Chemistry, Manipal Institute of Technology, Manipal Academy of Higher Education Manipal Karnataka 576104 India nitin.shetty@manipal.edu.
  • Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education Manipal Karnataka 576104 India.

ORCID-Profile: Nitinkumar S Shetty

Zitieren

APA

Dsouza, A., Subrahmanyam, V. M., & Shetty, N. S. (2026). Thiazole–driven heterocyclic hybrids as EGFR inhibitors: progress in synthesis and anticancer applications. RSC Advances, 16(1), 510-567. https://doi.org/10.1039/d5ra04838a

Vancouver

Dsouza A, Subrahmanyam VM, Shetty NS. Thiazole–driven heterocyclic hybrids as EGFR inhibitors: progress in synthesis and anticancer applications. RSC Advances. 2026;16(1):510-567. doi:10.1039/d5ra04838a

BibTeX
@article{Dsouza2026,
  author = {Dsouza, Ancilla and Subrahmanyam, V M and Shetty, Nitinkumar S},
  title = {Thiazole–driven heterocyclic hybrids as EGFR inhibitors: progress in synthesis and anticancer applications},
  journal = {RSC Advances},
  year = {2026},
  volume = {16},
  number = {1},
  pages = {510--567},
  doi = {10.1039/d5ra04838a}
}
Kostenlos starten →